sec filing
CY
NASDAQ · CYTK
Cytokinetics, Incorporated
Healthcare · Biotechnology
$69.31
Down-$3.14 (-4.33%)
Updated Sep 16, 2026, 10:00 AM
SID Score
5.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 7.23B
- P/E ratio
- -9.7
- Dividend yield
- 0.00%
- 52-week range
- $47.22 – $88.31
- Volume
- 2.58M
- Avg. volume
- 2.02M
Price performance
CYTK price history
1M range · 20 trading sessions · Daily adjusted prices
CYTK closed at $69.31 after 20 trading sessions, down 8.92% for the selected period.
- Last close
- $69.31
- Period change
- -8.92%
- Period low
- $69.31
- Period high
- $79.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $72.13 | $72.19 | $68.55 | $69.31 | 2.58M |
| Sep 14, 2026 | $73.505 | $74.65 | $72.34 | $72.45 | 1.53M |
| Sep 11, 2026 | $74.66 | $75.98 | $73.50 | $73.77 | 1.72M |
| Sep 10, 2026 | $73.23 | $75.10 | $73.13 | $73.62 | 1.44M |
| Sep 9, 2026 | $74.31 | $74.89 | $73.52 | $74.11 | 1.42M |
| Sep 8, 2026 | $72.39 | $76.805 | $72.39 | $75.35 | 1.92M |
| Sep 4, 2026 | $73.04 | $74.01 | $72.255 | $72.72 | 1.14M |
| Sep 3, 2026 | $73.55 | $74.225 | $71.41 | $73.95 | 1.59M |
| Sep 2, 2026 | $71.90 | $73.70 | $70.42 | $71.93 | 1.61M |
| Sep 1, 2026 | $69.85 | $72.455 | $69.83 | $71.40 | 1.9M |
| Aug 31, 2026 | $71.54 | $71.79 | $69.31 | $70.91 | 3.08M |
| Aug 28, 2026 | $73.88 | $74.42 | $71.66 | $72.09 | 4.36M |
| Aug 27, 2026 | $78.84 | $79.1288 | $77.84 | $77.90 | 1.11M |
| Aug 26, 2026 | $77.91 | $79.875 | $76.70 | $79.20 | 1.24M |
| Aug 25, 2026 | $77.93 | $78.72 | $77.21 | $77.46 | 1.26M |
| Aug 24, 2026 | $77.20 | $77.99 | $75.65 | $77.09 | 1.21M |
| Aug 21, 2026 | $77.30 | $77.70 | $76.65 | $76.84 | 1.52M |
| Aug 20, 2026 | $77.36 | $77.62 | $76.14 | $77.18 | 1.65M |
| Aug 19, 2026 | $77.23 | $77.88 | $76.17 | $77.74 | 1.51M |
| Aug 18, 2026 | $75.57 | $76.81 | $74.76 | $76.10 | 1.65M |
Latest CYTK news
The latest Smart Investors Daily articles mentioning CYTK.
Stock researchCompany · Overview
CYTK research
Overview
Company profile and research snapshot.
Company profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $79.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Barclays | Overweight | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.